Founded in Cambridge, MA, SynDevRx is dedicated to advancing cancer treatment through its pioneering work in metabo-oncology, focusing on the intersection of obesity and cancer. The company develops polymer-based drug conjugates designed to enhance the efficacy of small molecule drugs. SynDevRx aims to address the overlooked metabolic states in cancer patients, particularly those with insulin resistance, to improve patient outcomes.
Key figures and investors in SynDevRx include leading experts in oncology and metabolic research, though specific names are not publicly disclosed. The company has made significant strides in developing innovative treatments that target the metabolic pathways exploited by cancer cells. SynDevRx's contributions have the potential to revolutionize cancer therapy by addressing a critical and often neglected aspect of cancer progression and metastasis.
